Literature DB >> 16751785

Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.

M Snell1, C Chau, D Hendrix, R Fox, K A Downes, R Creger, H Meyerson, M J Telen, M J Laughlin, H M Lazarus, R Yomtovian.   

Abstract

While immune hemolysis due to donor isohemagglutinin (IH) production often complicates minor ABO incompatible peripheral blood hematopoietic stem cell transplantation (PBSCT), it is not known if this occurs with umbilical cord blood transplantation (UCBT). We compared IH production and hemolysis following minor ABO allogeneic PBSCT and UCBT. We reviewed 24 ABO minor incompatible allogeneic PBSCTs and 14 ABO minor incompatible UCBTs. Patients were evaluated for donor-derived IH by reverse ABO grouping. Evaluation of hemolysis was based on clinical and laboratory findings of anemia associated with increased RBC transfusion need, concomitant with the appearance of donor-derived IH. Of the 24 ABO minor incompatible allogeneic PBSCTs, 15 produced donor-derived IH from 6 to 88 days following transplantation, with seven of 15 patients exhibiting clinically evident hemolysis. There was no significant difference in days to leukocyte engraftment or infused CD34 cells in patients with or without donor-derived IH. None of the 14 patients receiving ABO incompatible UCBTs showed evidence of donor-derived IH following transplantation with a median follow-up of 60 days. We conclude that donor IHs are not produced in patients undergoing minor ABO incompatible UCBTs suggesting fundamental immunologic differences between allogeneic PBSCT and UCBT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751785     DOI: 10.1038/sj.bmt.1705409

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  "No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.

Authors:  Parastoo B Dahi; Doris M Ponce; Sean Devlin; Katherine L Evans; Marissa N Lubin; Anne Marie Gonzales; Joann Tonon; Richard Meagher; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-18       Impact factor: 5.742

2.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

3.  ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.

Authors:  Yang Chen; Xiaoju Wan; Yuan Cao; Huiru Wang; Dandan Han; Yuangyuang Zhang; Wen Yao; Kaidi Song; Qian Fan; Xiaoyu Zhu; Ziming Sun; Huilan Liu
Journal:  Blood Transfus       Date:  2021-07-02       Impact factor: 3.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.